145 related articles for article (PubMed ID: 37074863)
1. Transcription Factor Immunohistochemistry in the Classification of Pituitary Neuroendocrine Tumor/Adenoma: Proposal in a Limited-Resource Setting.
Sood R; Chatterjee D; Dutta P; Radotra BD
Arch Pathol Lab Med; 2024 Feb; 148(2):178-189. PubMed ID: 37074863
[TBL] [Abstract][Full Text] [Related]
2. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
3. The Role of T-box Transcription Factor in a Pituitary Adenoma Diagnostic Algorithm.
McDonald WC; McDonald KN; Helmer JA; Ho B; Wang A; Banerji N
Arch Pathol Lab Med; 2021 May; 145(5):592-598. PubMed ID: 32991684
[TBL] [Abstract][Full Text] [Related]
4. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M; Schüller U; Hagel C; Saeger W
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
[TBL] [Abstract][Full Text] [Related]
5. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
6. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
7. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
8. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors.
Mete O; Asa SL
Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227
[TBL] [Abstract][Full Text] [Related]
9. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
10. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
11. Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma.
McDonald WC; Banerji N; McDonald KN; Ho B; Macias V; Kajdacsy-Balla A
Arch Pathol Lab Med; 2017 Jan; 141(1):104-112. PubMed ID: 27227698
[TBL] [Abstract][Full Text] [Related]
12. Overview of the 2017 WHO Classification of Pituitary Tumors.
Mete O; Lopes MB
Endocr Pathol; 2017 Sep; 28(3):228-243. PubMed ID: 28766057
[TBL] [Abstract][Full Text] [Related]
13. Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives.
Wan XY; Chen J; Wang JW; Liu YC; Shu K; Lei T
Curr Med Sci; 2022 Dec; 42(6):1111-1118. PubMed ID: 36544040
[TBL] [Abstract][Full Text] [Related]
14. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.
Nishioka H; Inoshita N; Mete O; Asa SL; Hayashi K; Takeshita A; Fukuhara N; Yamaguchi-Okada M; Takeuchi Y; Yamada S
Endocr Pathol; 2015 Dec; 26(4):349-55. PubMed ID: 26481628
[TBL] [Abstract][Full Text] [Related]
15. Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2020 Jun; 31(2):150-155. PubMed ID: 32193825
[TBL] [Abstract][Full Text] [Related]
16. Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms.
Inomoto C; Tahara S; Oyama K; Kimura M; Matsuno A; Teramoto A; Osamura RY
Brain Tumor Pathol; 2021 Jul; 38(3):183-188. PubMed ID: 34269950
[TBL] [Abstract][Full Text] [Related]
17. A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
Woo CS; Ho RS; Ho G; Lau HT; Fong CH; Chang JY; Leung EK; Tang LC; Ma IK; Lee AC; Lui DT; Woo YC; Chow WS; Leung GK; Tan KC; Lam KS; Lee CH
Front Endocrinol (Lausanne); 2024; 15():1368944. PubMed ID: 38756997
[TBL] [Abstract][Full Text] [Related]
18. A review of multiomics platforms in pituitary adenoma pathogenesis.
Mouchtouris N; Smit RD; Piper K; Prashant G; Evans JJ; Karsy M
Front Biosci (Landmark Ed); 2022 Mar; 27(3):77. PubMed ID: 35345309
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs.
Vallette-Kasic S; Figarella-Branger D; Grino M; Pulichino AM; Dufour H; Grisoli F; Enjalbert A; Drouin J; Brue T
J Clin Endocrinol Metab; 2003 Jul; 88(7):3050-6. PubMed ID: 12843142
[TBL] [Abstract][Full Text] [Related]
20. Observation of Clinicopathologic Features of Pituitary Adenoma With Neuronal Differentiation.
Zheng L; Yan X; Hu C; Zhang P; Chen Y; Zheng Q; Hu L; Wang M; Li G; Wu P; Jiang C; Tian J; Zhang S; Wang X
Front Endocrinol (Lausanne); 2022; 13():848762. PubMed ID: 35370935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]